315 related articles for article (PubMed ID: 15171257)
1. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its interdigitation with chromatin.
Baylin SB
Novartis Found Symp; 2004; 259():226-33; discussion 234-7, 285-8. PubMed ID: 15171257
[TBL] [Abstract][Full Text] [Related]
2. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
Stirzaker C; Song JZ; Davidson B; Clark SJ
Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic interplay between histone modifications and DNA methylation in gene silencing.
Vaissière T; Sawan C; Herceg Z
Mutat Res; 2008; 659(1-2):40-8. PubMed ID: 18407786
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
Teodoridis JM; Strathdee G; Brown R
Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
[TBL] [Abstract][Full Text] [Related]
6. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer.
Wang LG; Beklemisheva A; Liu XM; Ferrari AC; Feng J; Chiao JW
Mol Carcinog; 2007 Jan; 46(1):24-31. PubMed ID: 16921492
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic control of ovarian function: the emerging role of histone modifications.
LaVoie HA
Mol Cell Endocrinol; 2005 Nov; 243(1-2):12-8. PubMed ID: 16219412
[TBL] [Abstract][Full Text] [Related]
8. Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines.
Osada H; Tatematsu Y; Sugito N; Horio Y; Takahashi T
Mol Carcinog; 2005 Dec; 44(4):233-41. PubMed ID: 16163707
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
10. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation and chromatin - unraveling the tangled web.
Robertson KD
Oncogene; 2002 Aug; 21(35):5361-79. PubMed ID: 12154399
[TBL] [Abstract][Full Text] [Related]
12. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic targets in hematopoietic malignancies.
Claus R; Lübbert M
Oncogene; 2003 Sep; 22(42):6489-96. PubMed ID: 14528273
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
15. The clinical application of targeting cancer through histone acetylation and hypomethylation.
Gilbert J; Gore SD; Herman JG; Carducci MA
Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
Bhalla KN
J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic changes in cancer.
Grønbaek K; Hother C; Jones PA
APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
19. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
20. The theoretical basis of transcriptional therapy of cancer: can it be put into practice?
Melnick AM; Adelson K; Licht JD
J Clin Oncol; 2005 Jun; 23(17):3957-70. PubMed ID: 15867201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
